Author [ Title] Type Year
Filters: Author is Devlin, Sean M [Clear All Filters]
CD34-selected allogeneic hematopoietic stem cell transplantation for patients with relapsed, high-risk multiple myeloma. Biol Blood Marrow Transplant. 2015.
CD34-selected hematopoietic stem cell transplants conditioned with myeloablative regimens and anti-thymocyte globulin for advanced myelodysplastic syndrome: limited graft-versus-host disease without increased relapse. Biol Blood Marrow Transplant. 2015.
Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. Blood Adv. 2020;4(4):676-686.
Drugs as a Frequent Cause of Acute Rash in Patients After CD34-selected Peripheral Blood Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019..
Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation. J Clin Invest. 2020.
Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. N Engl J Med. 2020;382(9):822-834.
Pre-transplant cognitive dysfunction in advanced-age hematologic cancers: predictors and associated outcomes. Biol Blood Marrow Transplant. 2020..
Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity 1 with Novel Induction Regimens in Multiple Myeloma. Biol Blood Marrow Transplant. 2020.